Dova Pharmaceuticals Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for the use of Doptelet for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

The U.S Food and Drug Administration said on Monday it had approved Dova Pharmaceuticals Inc.’s drug to treat low blood platelet count in chronic liver disease (CLD) patients, who are scheduled to undergo a medical procedure.